Agrylin (anagrelide) is the first drug specifically approved for patients with essential thrombocythemia

    Agrylin (anagrelide) is the first drug specifically approved for patients with essential thrombocythemia.

    These patients have ELEVATED platelet counts...about six times higher than usual.

    Too many platelets increase the risk of thrombosis...leading to heart attack and stroke.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote